

## Supplementary Information

### (1*R*,4*S*,5*S*)-5-((3-hydroxypropyl)amino)-4-((1-methyl-1*H*-tetrazol-5-yl)thio)cyclopent-2-en-1-ol

Milene A. G. Fortunato <sup>1</sup>, Filipa Siopa <sup>1,\*</sup> and Carlos A. M. Afonso <sup>1\*</sup>

1. Research Institute for Medicines (iMed.Ulisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003, Lisboa, Portugal





Figure S1 <sup>1</sup>H-NMR spectrum of (1*R*,4*S*,5*S*)-5-((3-hydroxypropyl)amino)-4-((1-methyl-1*H*-tetrazol-5-yl)thio)cyclopent-2-en-1-ol (**3c**) in deuterium oxide.



**Figure S2**  $^{13}\text{C}$ -NMR spectrum of (1R,4S,5S)-5-((3-hydroxypropyl)amino)-4-((1-methyl-1H-tetrazol-5-yl)thio)cyclopent-2-en-1-ol (**3c**) in deuterium oxide.




Figure S3 HSQC spectrum of (1R,4S,5S)-5-((3-hydroxypropyl)amino)-4-((1-methyl-1H-tetrazol-5-yl)thio)cyclopent-2-en-1-ol (**3c**) in deuterium oxide.

FSMF#761 RT: 5.00 AV: 1 NL: 3.81E8  
T: FTMS + p ESI Full ms [50.00-750.00]




Figure S4 HRMS spectrum of (1R,4S,5S)-5-((3-hydroxypropyl)amino)-4-((1-methyl-1H-tetrazol-5-yl)thio)cyclopent-2-en-1-ol (3c).